Daiichi Sankyo

Patent cliffs & loss of exclusivity

Daiichi Sankyo is an innovative global healthcare company that discovers, develops and delivers new standards of care.

Company

Company Operating StatusActive
Email format{first}.{last}
Facebook URLhttps://www.facebook.com/daiichisankyous
Legal Entity Identifier353800XGIU2IHQGC9504
LinkedIn URLhttps://www.linkedin.com/company/daiichi-sankyo
Pitchbook URLhttps://pitchbook.com/profiles/company/51036-40
Seedtable URLhttps://seedtable.com/companies/daiichi-sankyo
Twitter URLhttps://twitter.com/daiichisankyous

7 upcoming patent cliffs

DrugIngredientTypeCliff
  1. SAVAYSAEDOXABAN TOSYLATESmall mol.Mar 2028
  2. SAVAYSAEDOXABAN TOSYLATESmall mol.Mar 2028
  3. SAVAYSAEDOXABAN TOSYLATESmall mol.Mar 2028
  4. VANFLYTAQUIZARTINIB DIHYDROCHLORIDESmall mol.Sep 2033
  5. VANFLYTAQUIZARTINIB DIHYDROCHLORIDESmall mol.Sep 2033
  6. TURALIOPEXIDARTINIB HYDROCHLORIDESmall mol.Jul 2038
  7. TURALIOPEXIDARTINIB HYDROCHLORIDESmall mol.Jul 2038
  8. Enhertufam-trastuzumab deruxtecan-nxkiBiologic—
  9. Datrowaydatopotamab deruxtecan-dlnkBiologic—

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.